LLY250502C705000
- 106.10
- -11.35-9.66%
Eli Lilly and Co Newsroom
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Eli Lilly & Co (LLY) Gets a Buy From TD Cowen
Research Alert: Lly Q1 Results: Top-line Beat, Bottom-line Miss, 2025 Sales Guidance Intact
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Wells Fargo Keeps Their Buy Rating on Eli Lilly & Co (LLY)
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $888
Eli Lilly Analyst Ratings
HSBC Downgrades Eli Lilly and Co(LLY.US) to Sell Rating, Cuts Target Price to $700
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,000
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $975 to $1,124
Cantor Fitzgerald Initiates Coverage On Eli Lilly With Overweight Rating, Announces Price Target of $975
Eli Lilly Analyst Ratings
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $989
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $900
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $928
Eli Lilly Analyst Ratings